FDA WARNING_LETTER - Novo Nordisk A/S - March 20, 2012

FDA WARNING_LETTER for Novo Nordisk A/S on March 20, 2012. Product: Drugs. Access full analysis and detailed observations.

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

FDA WARNING_LETTER for Novo Nordisk A/S on March 20, 2012. Product: Drugs. Access full analysis and detailed observations.

Violation Codes

21 CFR 211.113(b)

FD&C Act 501(a)(2)(B)

21 CFR 211

21 U.S.C. 356C(a)(1)

21 CFR 210

21 CFR 211.192

21 U.S.C. 381(a)(3)

21 U.S.C. 351(a)(2)(B)

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Novo Nordisk A/S

Inspection Date

March 20, 2012

Product Type

Drugs

Office

Department of Health and Human Services

People

Steven J. Lynn

ID: 3c85b108-b1bd-4f59-90aa-345fe3cc217f

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox